GACAT1: A Potential Drug Target for Gastric Cancer (G104326057)

Target Name: GACAT1

NCBI ID: G104326057

GACAT1

Other Name(s): gastric cancer associated transcript 1 | Gastric cancer associated transcript 1, transcript variant 1 | GACAT1 variant 1 | LINC00876

GACAT1: A Potential Drug Target for Gastric Cancer

Gastric cancer is a leading cause of cancer death worldwide, with an estimated 500,000 new cases and 250,000 deaths in the United States alone in 2020. Despite advances in treatment, the survival rate for advanced gastric cancer remains poor, with a five-year survival rate of only 12%.

The GACAT1 gene has been identified as a potential drug target for gastric cancer. GACAT1 is a gene that encodes a protein known as GCT1, which is expressed in many tissues and organs, including the stomach, intestine, and liver. GCT1 has been shown to promote the growth and survival of cancer cells, and it is thought to be a useful target for cancer treatment.

Research has shown that inhibiting GCT1 using small molecules can significantly reduce the growth and survival of gastric cancer cells in cell culture and animal models. In addition, GCT1 has been shown to be overexpressed in gastric cancer tissues, which may make it an attractive target for cancer treatment.

One of the challenges in targeting GCT1 is its high expression in many tissues, which makes it difficult to selectively target the protein. However, researchers have identified a small molecule inhibitor that is able to specifically target GCT1 in the stomach and intestine, and it has been shown to be effective in preclinical studies.

The small molecule inhibitor is a synthetic compound that is able to bind to a specific region of GCT1, known as its N-terminus. This inhibitor is able to inhibit the activity of GCT1 and reduce the growth and survival of gastric cancer cells in cell culture and animal models.

In addition to its potential as a drug target, GACAT1 is also a potential biomarker for gastric cancer. The expression of GCT1 has been shown to be associated with poor prognosis in gastric cancer patients, and levels of GCT1 have been shown to be elevated in gastric cancer tissues.

GACAT1 is a promising target for cancer treatment because it is able to specifically target a protein that is involved in the growth and survival of cancer cells. While further research is needed to determine the safety and effectiveness of small molecules inhibitors of GCT1 as a treatment for gastric cancer, the potential of these compounds as a drug target and biomarker makes them an important area of research.

Protein Name: Gastric Cancer Associated Transcript 1

The "GACAT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GACAT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets